Evidence map›Paper›PMID 33090333›Full record

ArticleTargeted oncology2020

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Julie G Fisher, David Tait, Elizabeth Garrett-Mayer, Susan Halabi, Pam K Mangat, Julian C Schink, Ricardo H Alvarez, Dan Veljovich, Timothy L Cannon, Pamela A Crilley and 9 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02693535 (Targeted Agent and Profiling Utilization Registry), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02693535 phase2recruitingnot on this map

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

TypeinterventionalSponsorAmerican Society of Clinical OncologyRan2016 to 2028Enrolled4,200ConditionsLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsArmsPalbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. The Role of Master Protocols in Pediatric Drug Development.Therapeutic innovation & regulatory science · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Julie G FisherLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
David TaitLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Elizabeth Garrett-MayerAmerican Society of Clinical Oncology, 2318 Mill Road, Alexandria, VA, 22314, USA.
Susan HalabiDuke University Medical Center, Durham, NC, USA.
Pam K MangatAmerican Society of Clinical Oncology, 2318 Mill Road, Alexandria, VA, 22314, USA. TAPURPublications@asco.org.
Julian C SchinkCancer Treatment Centers of America, Chicago, IL, USA.
Ricardo H AlvarezCancer Treatment Centers of America, Atlanta, GA, USA.
Dan VeljovichSwedish Cancer Institute, Seattle, WA, USA.
Timothy L CannonInova Schar Cancer Institute, Fairfax, VA, USA.
Pamela A CrilleyCancer Treatment Centers of America, Philadelphia, PA, USA.
Theodore PollockCancer Treatment Centers of America, Tulsa, OK, USA.
Carmen J CalfaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Tareq Al BaghdadiMichigan Cancer Research Consortium, Ypsilanti, MI, USA.
Ramya ThotaIntermountain Precision Genomics Cancer Clinic, Salt Lake City, UT, USA.
Nicole FlemingThe University of Texas MD Anderson Cancer Center, Sugarland, TX, USA.
Jared A CottaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Andrew L RygielAmerican Society of Clinical Oncology, 2318 Mill Road, Alexandria, VA, 22314, USA.
Sasha L WarrenAmerican Society of Clinical Oncology, 2318 Mill Road, Alexandria, VA, 22314, USA.
Richard L SchilskyAmerican Society of Clinical Oncology, 2318 Mill Road, Alexandria, VA, 22314, USA.
American Society of Clinical Oncology · USCancer Treatment Centers of America · USLevine Cancer Institute · USDuke Medical Center · USIntermountain Healthcare · USMichigan Cancer Research Consortium · USSylvester Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Miami · USVirginia Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets.

objectiveWith no known genomic targets predictive of sensitivity to cetuximab, cetuximab was evaluated in patients with breast cancer (BC), non-small cell lung cancer (NSCLC), and ovarian cancer (OC), without KRAS, NRAS, or BRAF mutations. PATIENTS AND

methodsEligible patients with advanced BC, NSCLC, and OC received a cetuximab loading dose, then weekly infusions (250 mg/m

resultsPatients with BC (n = 10), NSCLC (n = 10), and OC (n = 29) were enrolled between June 2016 and September 2018. No objective responses or stable disease for at least 16 weeks were observed in the BC and NSCLC cohorts. No objective responses and four patients with stable disease for at least 16 weeks were observed in the OC cohort. Six of 49 patients reported grade 3 or higher adverse events or serious adverse events at least possibly related to cetuximab.

conclusionsCetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC without KRAS, NRAS, or BRAF mutations. CLINICAL

trial registrationNCT02693535 (26 February, 2016).

Indexed as

Antineoplastic Agents, ImmunologicalBreast NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Ovarian EpithelialCetuximabLung NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedProto-Oncogene Proteins B-rafRegistriesAntineoplastic Agents, ImmunologicalCetuximabProto-Oncogene Proteins B-raf

Identifiers

PMID33090333
OpenAlexW3094617408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.